Indeed, HMGB1 is released in the TME after chemotherapy in breast and pancreatic cancer patients [93], and high HMGB1 levels have been associated with poor response to treatment in pancreatic and triple negative breast cancer patients [94,95]. Here, HMGB1 is linked to pancreatic neoplasm.